Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Arquivos brasileiros de oftalmologia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492020000100010 |
Resumo: | ABSTRACT Purpose: To study the cost-effectiveness of ranibizumab and bevacizumab for the treatment of age-related macular degeneration. Methods: We used a decision tree model to analyze the cost-effectiveness of ranibizumab and bevacizumab for the treatment of age-related macular degeneration, from the Brazilian Public Health System (SUS) perspective. Ranibizumab and bevacizumab were administered to patients with the same treatment procedure, and the difference in treatment costs was calculated based on the cost of the drugs. Direct costs were estimated using the information provided by the Brazilian SUS. Effectiveness in terms of quality-adjusted life years (QALYs) was calculated based on the utility values for visual impairment. Incremental cost-effectiveness ratio was calculated by comparing both treatments. The analytical horizon was one year. Results: The decision tree analysis showed that the difference in treatment effectiveness was 0.01 QALY. Incremental cost-effectiveness ratio showed that ranibizumab treatment required an incremental annual cost of more than R$ 2 million to generate 1 additional QALY, as compared to bevacizumab. Conclusions: From the Brazilian SUS perspective, bevacizumab is more cost-effective than ranibizumab for the treatment of neovascular age-related macular degeneration. Its use could allow potential annual savings in health budget. |
id |
CBO-2_e391c9c26fb9cb19433110ef4db07f12 |
---|---|
oai_identifier_str |
oai:scielo:S0004-27492020000100010 |
network_acronym_str |
CBO-2 |
network_name_str |
Arquivos brasileiros de oftalmologia (Online) |
repository_id_str |
|
spelling |
Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspectiveAge-related macular degenerationCost-benefit analysisRetinaBevacizumabRanibizumabABSTRACT Purpose: To study the cost-effectiveness of ranibizumab and bevacizumab for the treatment of age-related macular degeneration. Methods: We used a decision tree model to analyze the cost-effectiveness of ranibizumab and bevacizumab for the treatment of age-related macular degeneration, from the Brazilian Public Health System (SUS) perspective. Ranibizumab and bevacizumab were administered to patients with the same treatment procedure, and the difference in treatment costs was calculated based on the cost of the drugs. Direct costs were estimated using the information provided by the Brazilian SUS. Effectiveness in terms of quality-adjusted life years (QALYs) was calculated based on the utility values for visual impairment. Incremental cost-effectiveness ratio was calculated by comparing both treatments. The analytical horizon was one year. Results: The decision tree analysis showed that the difference in treatment effectiveness was 0.01 QALY. Incremental cost-effectiveness ratio showed that ranibizumab treatment required an incremental annual cost of more than R$ 2 million to generate 1 additional QALY, as compared to bevacizumab. Conclusions: From the Brazilian SUS perspective, bevacizumab is more cost-effective than ranibizumab for the treatment of neovascular age-related macular degeneration. Its use could allow potential annual savings in health budget.Conselho Brasileiro de Oftalmologia2020-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492020000100010Arquivos Brasileiros de Oftalmologia v.83 n.1 2020reponame:Arquivos brasileiros de oftalmologia (Online)instname:Conselho Brasileiro de Oftalmologia (CBO)instacron:CBO10.5935/0004-2749.20200020info:eu-repo/semantics/openAccessNunes,Renata PortellaHirai,Flávio EduardoRodrigues,Eduardo BuchelleFarah,Michel Eideng2020-02-21T00:00:00Zoai:scielo:S0004-27492020000100010Revistahttp://aboonline.org.br/https://old.scielo.br/oai/scielo-oai.phpaboonline@cbo.com.br||abo@cbo.com.br1678-29250004-2749opendoar:2020-02-21T00:00Arquivos brasileiros de oftalmologia (Online) - Conselho Brasileiro de Oftalmologia (CBO)false |
dc.title.none.fl_str_mv |
Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective |
title |
Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective |
spellingShingle |
Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective Nunes,Renata Portella Age-related macular degeneration Cost-benefit analysis Retina Bevacizumab Ranibizumab |
title_short |
Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective |
title_full |
Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective |
title_fullStr |
Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective |
title_full_unstemmed |
Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective |
title_sort |
Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective |
author |
Nunes,Renata Portella |
author_facet |
Nunes,Renata Portella Hirai,Flávio Eduardo Rodrigues,Eduardo Buchelle Farah,Michel Eid |
author_role |
author |
author2 |
Hirai,Flávio Eduardo Rodrigues,Eduardo Buchelle Farah,Michel Eid |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Nunes,Renata Portella Hirai,Flávio Eduardo Rodrigues,Eduardo Buchelle Farah,Michel Eid |
dc.subject.por.fl_str_mv |
Age-related macular degeneration Cost-benefit analysis Retina Bevacizumab Ranibizumab |
topic |
Age-related macular degeneration Cost-benefit analysis Retina Bevacizumab Ranibizumab |
description |
ABSTRACT Purpose: To study the cost-effectiveness of ranibizumab and bevacizumab for the treatment of age-related macular degeneration. Methods: We used a decision tree model to analyze the cost-effectiveness of ranibizumab and bevacizumab for the treatment of age-related macular degeneration, from the Brazilian Public Health System (SUS) perspective. Ranibizumab and bevacizumab were administered to patients with the same treatment procedure, and the difference in treatment costs was calculated based on the cost of the drugs. Direct costs were estimated using the information provided by the Brazilian SUS. Effectiveness in terms of quality-adjusted life years (QALYs) was calculated based on the utility values for visual impairment. Incremental cost-effectiveness ratio was calculated by comparing both treatments. The analytical horizon was one year. Results: The decision tree analysis showed that the difference in treatment effectiveness was 0.01 QALY. Incremental cost-effectiveness ratio showed that ranibizumab treatment required an incremental annual cost of more than R$ 2 million to generate 1 additional QALY, as compared to bevacizumab. Conclusions: From the Brazilian SUS perspective, bevacizumab is more cost-effective than ranibizumab for the treatment of neovascular age-related macular degeneration. Its use could allow potential annual savings in health budget. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-02-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492020000100010 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492020000100010 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.5935/0004-2749.20200020 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Conselho Brasileiro de Oftalmologia |
publisher.none.fl_str_mv |
Conselho Brasileiro de Oftalmologia |
dc.source.none.fl_str_mv |
Arquivos Brasileiros de Oftalmologia v.83 n.1 2020 reponame:Arquivos brasileiros de oftalmologia (Online) instname:Conselho Brasileiro de Oftalmologia (CBO) instacron:CBO |
instname_str |
Conselho Brasileiro de Oftalmologia (CBO) |
instacron_str |
CBO |
institution |
CBO |
reponame_str |
Arquivos brasileiros de oftalmologia (Online) |
collection |
Arquivos brasileiros de oftalmologia (Online) |
repository.name.fl_str_mv |
Arquivos brasileiros de oftalmologia (Online) - Conselho Brasileiro de Oftalmologia (CBO) |
repository.mail.fl_str_mv |
aboonline@cbo.com.br||abo@cbo.com.br |
_version_ |
1754209030462504960 |